The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Kura Oncology and Kyowa Kirin Collaborate to Develop and Commercialize Ziftomenib for Acute Leukemias
Nov 20, 2024•over 1 year ago
Contract Type
partnership
San DiegoBiotechnology Research
Description
Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. have announced a global strategic collaboration to jointly develop and commercialize ziftomenib, with Kura leading the U.S. development and commercial activities while Kyowa Kirin has exclusive commercialization rights outside the U.S
Company Information
Company
Kura Oncology
Location
San Diego, California, United States
About
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.
San DiegoBiotechnology Research